APIDRA (insulin glulisine)
SHORT-ACTING INSULINS · TYPE 2 DIABETES MELLITUS ·+1
Sanofi-Aventis U.S.
Drug class
Short-Acting Insulins
Short-acting insulins are a class of antidiabetic agents, primarily consisting of regular human insulin, designed to mimic physiologic mealtime insulin release. Read more about Short-Acting Insulins
71 drugs in this class 10 manufacturers
Drugs in Short-Acting Insulins
HUMULIN R U-500 (insulin regular, human)
SHORT-ACTING INSULINS · DIABETES MELLITUS WITH SEVERE INSULIN RESISTANCE
Eli Lilly and Company
NOVOLIN R (insulin regular, human)
SHORT-ACTING INSULINS · TYPE 2 DIABETES MELLITUS ·+5
NOVO NORDISK
HUMALOG KWIKPEN U-100 (insulin lispro)
SHORT-ACTING INSULINS · TYPE 2 DIABETES MELLITUS ·+2
Eli Lilly and Company
APIDRA SOLOSTAR (insulin glulisine)
SHORT-ACTING INSULINS · TYPE 2 DIABETES MELLITUS ·+1
Sanofi-Aventis U.S.
NOVOLIN R (insulin regular, human)
SHORT-ACTING INSULINS · TYPE 2 DIABETES MELLITUS ·+5
Novo Nordisk
HUMULIN R U-500 KWIKPEN (insulin regular, human)
SHORT-ACTING INSULINS · DIABETES MELLITUS WITH SEVERE INSULIN RESISTANCE
Eli Lilly and Company
AFREZZA (insulin regular, human)
SHORT-ACTING INSULINS · TYPE 2 DIABETES MELLITUS ·+1
MANNKIND CORPOR
FIASP (insulin aspart (niacinamide))
SHORT-ACTING INSULINS · TYPE 2 DIABETES MELLITUS ·+2
NOVO NORDISK
Filter & compare in the drug finder →
Opens the drug finder with Short-Acting Insulins preselected. Add indication or manufacturer filters there.
Short-acting insulins are a class of antidiabetic agents, primarily consisting of regular human insulin, designed to mimic physiologic mealtime insulin release.
They work by binding to cellular insulin receptors, stimulating peripheral glucose uptake into skeletal muscle and adipose tissue while suppressing hepatic glucose production.
Typically demonstrating an onset of action within 30 to 60 minutes and a duration of about five to eight hours, this class is primarily indicated for glycemic control in type 1 and type 2 diabetes mellitus.
Additionally, short-acting regular insulin serves as a mainstay of intravenous therapy in acute metabolic emergencies such as diabetic ketoacidosis and hyperosmolar hyperglycemic states.
-
fda.gov
Short-acting insulins are a class of antidiabetic agents, primarily consisting of regular human insulin, designed to mimic physiologic mealtime insulin release Typically demonstrating an onset of action within 30 to 60 minutes and a duration of about five to eight hours, this class is primarily indicated for glycemic control in type 1 and type 2 diabetes mellitus
-
nih.gov
Short-acting insulins are a class of antidiabetic agents, primarily consisting of regular human insulin, designed to mimic physiologic mealtime insulin release Typically demonstrating an onset of action within 30 to 60 minutes and a duration of about five to eight hours, this class is primarily indicated for glycemic control in type 1 and type 2 diabetes mellitus Additionally, short-acting regular insulin serves as a mainstay of intravenous therapy in acute metabolic emergencies such as diabetic...
-
fda.gov
They work by binding to cellular insulin receptors, stimulating peripheral glucose uptake into skeletal muscle and adipose tissue while suppressing hepatic glucose production Additionally, short-acting regular insulin serves as a mainstay of intravenous therapy in acute metabolic emergencies such as diabetic ketoacidosis and hyperosmolar hyperglycemic states
-
fda.gov
They work by binding to cellular insulin receptors, stimulating peripheral glucose uptake into skeletal muscle and adipose tissue while suppressing hepatic glucose production
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.